Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.70 USD
Change Today 0.00 / 0.00%
Volume 203.8K
CUR On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 2:43 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

neuralstem inc (CUR) Snapshot

Open
$1.71
Previous Close
$1.70
Day High
$1.73
Day Low
$1.66
52 Week High
09/2/14 - $4.11
52 Week Low
06/2/15 - $1.46
Market Cap
153.6M
Average Volume 10 Days
444.2K
EPS TTM
$-0.25
Shares Outstanding
90.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEURALSTEM INC (CUR)

neuralstem inc (CUR) Related Bloomberg News

View More Bloomberg News

neuralstem inc (CUR) Details

Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds. The company’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of all types. Its clinical program products include NSI-566, which is in ongoing Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as in Phase I clinical trial for chronic spinal cord injury. The company’s clinical development products also comprise NSI–566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; NSI–189 that completed Phase Ia and Ib trials for the treatment of major depressive disorders; and NSI–189, which is in Phase Ib preparation for cognitive deficit in schizophrenia. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

21 Employees
Last Reported Date: 05/8/15
Founded in 1996

neuralstem inc (CUR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $651.2K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $1.2M
Compensation as of Fiscal Year 2014.

neuralstem inc (CUR) Key Developments

U.S. District Court for the District of Maryland Dismisses Patent Infringement Lawsuit Against Neuralstem

Neuralstem announced on July 23, 2015, that the U.S. District Court for the District of Maryland has dismissed a patent infringement case brought against it by StemCells (STEM) with prejudice in favor of Neuralstem, on July 22, 2015.

Neuralstem, Inc.(NasdaqCM:CUR) added to NASDAQ Composite Index

Neuralstem, Inc. has been added to Nasdaq Composite Index.

Neuralstem, Inc. Primary Exchange Listing will Change to Nasdaq Capital Market from NYSE MKT LLC

Effective July 13, 2015, Neuralstem, Inc. primary exchange listing will change to Nasdaq Capital Market from NYSE MKT LLC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CUR:US $1.70 USD 0.00

CUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.23 USD +0.04
International Stem Cell Corp $0.05 USD -0.0025
Ocata Therapeutics Inc $4.31 USD -0.3151
ReNeuron Group PLC 5.75 GBp +0.05
StemCells Inc $0.42 USD -0.0231
View Industry Companies
 

Industry Analysis

CUR

Industry Average

Valuation CUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9,077.7x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7,013.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEURALSTEM INC, please visit www.neuralstem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.